logo
Plus   Neg
Share
Email
Comment

Bristol-Myers, Meso Scale To Develop Diagnostic Assays For Alzheimer's Disease

Bristol-Myers Squibb Co. (BMY) and Meso Scale Discovery announced they have entered an agreement to develop diagnostic assays that will measure cerebrospinal fluid biomarkers for use in Alzheimer's disease research.

As per the terms of the agreement, the companies will develop these assays based on the Meso Scale Discovery MULTI-ARRAY technology platform. Meso Scale Discovery will commercialize the assays for Alzheimer's disease research and drug development, and plans to release the assays in the second quarter of 2012. Terms of the agreement were not disclosed.

Alzheimer's disease is a progressive brain disease that impairs memory, interferes with thinking and ultimately destroys the ability of an individual to carry out simple tasks. The disease is a continuum, with damage to the brain starting long before the onset of dementia.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Shares of BP Plc were losing around 2 percent in the morning trading in London after the British energy giant said Tuesday that it now expects to take a post-tax non-operating charge of around $1.7 billion in its fourth quarter for Deepwater Horizon settlement program. BlackBerry Ltd. has introduced a new a cloud-based cybersecurity program that will scan automakers' software for threats amid increased concerns about hacking in Internet-connected cars. BlackBerry Jarvis, the transformational software cybersecurity product, helps carmakers detect security flaws in software before it goes into their vehicles. General Motors Co. said it plans to mass-produce self driving cars that will have no steering wheel, pedals or manual controls by 2019. The automaker has filed a safety petition with the Department of Transportation for its fourth-generation self-driving Cruise AV, its first production-ready vehicle built from the start to operate safely on its own.
comments powered by Disqus
Follow RTT